SANTA CRUZ, CA, USA — “We are honored to have someone of Mikael’s caliber join our team,” said RealSeq Biosciences CEO, Sergio Barberan-Soler, Ph.D. “His expertise will be invaluable as we continue to develop innovative solutions for the growing field of RNA fragmentomics and novel biomarker strategies.”

Mikael Kubista, Ph.D. is a world-renowned expert in gene expression and qPCR analysis. He is a prolific inventor of innovative technologies for small/ miRNA analysis and liquid biopsy. As a co-founder and director of TATAA Biocenter, he was instrumental in achieving global status as a leading CRO for molecular analysis. Dr. Kubista serves as an advisor to biotech and pharmaceutical companies around the world working out of the GoCo Health Innovation City in western Sweden.

“I am excited to join RealSeq to help them to expand their ground-breaking RNA fragmentomics technologies and foster key industry partnerships,” said Dr. Kubista. “Their platform has the potential to revolutionize RNA-based biomarker discovery and liquid biopsy. I am looking forward to being a part of that.”

Dr. Kubista has published more than 400 scientific papers and is the recipient of numerous awards. Currently, he heads the Laboratory of Gene Expression at the Institute of Biotechnology, BIOCEV, Czech Academy of Sciences and is among the world’s 2 % most cited researchers.

About RealSeq Biosciences:

RealSeq’s offices and laboratories are located in Santa Cruz, California. The company specializes in developing groundbreaking and innovative technologies focusing on RNA fragmentomics, small RNA analysis, NGS research tools and biomarkers. RealSeq’s visionary approach to RNA fragmentomics-based diagnostics is making development and use of dynamic markers of disease a new reality.